Integra LifeSciences said it priced $450 million in 9.5% senior secured notes due 2033, with the offering expected to close around Oct. 19. Proceeds from the notes, combined with borrowings under new credit facilities, will be used to refinance the company's existing credit facilities. The new debt will carry guarantees from the company's wholly owned U.S. subsidiaries that back its existing secured credit facilities.
Integra LifeSciences HoldingsIntegra prices $450M in 9.5% senior secured notes to refinance existing credit facilities, adding high-cost debt.
